

Two Weeks to go until the RNA Therapeutics Conference Takes Place

Smi Group reports: registration closing soon, secure your place at the RNA Therapeutics Conference with two weeks left to go!

LONDON, NON UNITED STATES OR CANADA, UNITED KINGDOM, January 26, 2022 /EINPresswire.com/ -- With just two weeks remaining until SMi's 13th Annual [RNA Therapeutics](#) Virtual Conference convenes on 9th – 10th February 2022, interested attendees are being encouraged to register to secure their place.

Featuring over 20 engaging presentations from senior experts, including 3 spotlight sessions on leading advances of RNA developments and 2 cutting edge panel discussions.

Interested parties can register for virtual attendance at: <http://www.therapeutics-rna.com/PR5EIN>

Heinrich Haas, VP RNA Formulation and Drug Delivery, BioNTech - Conference Chair invites you to join the conference, by sharing their invitation letter below:

Dear Colleagues,

It is with great pleasure and delight that I welcome you to SMi's highly anticipated RNA Therapeutics virtual conference taking place on the 9th-10th of February 2022. The 13th annual conference will bring together expertise from individuals in multiple disciplines in the field addressing the key drivers of this rapidly growing industry.



The banner features a blue background with orange and red abstract shapes resembling RNA structures. At the top right is the SMi logo. The text is arranged as follows:

- Top right: SMi logo
- Top center: *SMi's 13th Annual...*
- Center: **RNA Therapeutics Conference**
9 - 10 February 2022
Virtual Conference: Online Access Only
- Bottom center (in a white box): *Bolstering the latest advances and opportunities in RNA-based medicine*
- Bottom: **www.therapeutics-rna.com | #SMiRNA**

We have witnessed significant growth and innovation in the RNA landscape and this 2-day agenda will offer a series of presentations through which you will gain insights from leading pharmaceutical, biotech and regulatory representatives on the ever-growing field. Furthermore, with the heightened spotlight on [mRNA](#) vaccines in the fight against COVID-19, this year's pre-conference focus day will address vaccines and anti-virals in the RNA industry.

Delegates stand to gain many valuable insights from this event such as:

- Learnings and takeaways exploring the industry's pivotal role in the global pandemic
- Recent developments in novel and targeted RNA delivery systems
- Updates in RNA Interference with insights from leading biotechs revolutionising the RNA therapeutics landscape
- Outlooks in advancing targets and target discovery for RNA therapeutics

I look forward to welcoming you to this must attend conference in London this coming February.

Yours sincerely,

Heinrich Haas, VP RNA Formulation and Drug Delivery, BioNTech
(Conference Chair)

To view the full two-day agenda and speaker interviews from leading pharma companies such as: MiNA Therapeutics, Envisagenics and Miescher Pharma visit: <http://www.therapeutics-rna.com/PR5EIN>

Sponsors: BIA Separations | eTheRNA Immunotherapies | Thermo Fisher

For sponsorship enquiries contact Andrew Gibbons on +44 (0) 20 7827 6156 or e-mail agibbons@smi-online.co.uk

For media enquiries or a press pass contact Marketing, Nikisha Galoria on +44 (0) 20 7827 6154 or email ngaloria@smi-online.co.uk

RNA Therapeutics 2022

9 – 10 February 2022

Virtual Attendance: Online Access Only

#SMiRNA

<http://www.therapeutics-rna.com/PR5EIN>

--- ENDS ---

About [SMi Group](#):

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We

create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Nikisha Galoria

SMi Group

02078276000

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/561554460>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.